IL106968A - Potentiation of immunogenic response - Google Patents

Potentiation of immunogenic response

Info

Publication number: IL106968A
Authority: IL; Israel
Prior art keywords: antigen; cells; physiochemical; animal; vaccine
Prior art date: 1992-09-14

Application number

IL10696893A

Other languages

English (en)

Other versions

IL106968A0 (en

Inventor

Robert S Becker

Karen Biscardi

Laura Ferguson

Lorne Erdile

Original Assignee

Connaught Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-14

Filing date

1993-09-10

Publication date

1999-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25479200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL106968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-09-10 Application filed by Connaught Lab filed Critical Connaught Lab

1993-12-28 Publication of IL106968A0 publication Critical patent/IL106968A0/xx

1999-05-23 Priority to IL13007599A priority Critical patent/IL130075A0/xx

1999-10-28 Publication of IL106968A publication Critical patent/IL106968A/en

Links

230000009851 immunogenic response Effects 0.000 title description 5
239000000427 antigen Substances 0.000 claims abstract description 112
108091007433 antigens Proteins 0.000 claims abstract description 112
102000036639 antigens Human genes 0.000 claims abstract description 112
230000028993 immune response Effects 0.000 claims abstract description 27
210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 25
210000004027 cell Anatomy 0.000 claims abstract description 15
241000712461 unidentified influenza virus Species 0.000 claims abstract description 6
241001465754 Metazoa Species 0.000 claims description 33
108090000623 proteins and genes Proteins 0.000 claims description 24
102000004169 proteins and genes Human genes 0.000 claims description 21
210000001744 T-lymphocyte Anatomy 0.000 claims description 20
229960005486 vaccine Drugs 0.000 claims description 18
230000004044 response Effects 0.000 claims description 15
230000002163 immunogen Effects 0.000 claims description 10
230000000890 antigenic effect Effects 0.000 claims description 7
206010022000 influenza Diseases 0.000 claims description 7
230000002209 hydrophobic effect Effects 0.000 claims description 5
108010077805 Bacterial Proteins Proteins 0.000 claims description 2
108700006640 OspA Proteins 0.000 claims description 2
229940099789 ospa protein Drugs 0.000 claims description 2
230000002195 synergetic effect Effects 0.000 claims 3
241000589969 Borreliella burgdorferi Species 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 22
230000003612 virological effect Effects 0.000 abstract description 6
241000700605 Viruses Species 0.000 description 14
101710105714 Outer surface protein A Proteins 0.000 description 9
241000700198 Cavia Species 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
238000000034 method Methods 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
238000011260 co-administration Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000030741 antigen processing and presentation Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
210000002443 helper t lymphocyte Anatomy 0.000 description 4
230000003993 interaction Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000589970 Spirochaetales Species 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
101800000385 Transmembrane protein Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000008614 cellular interaction Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
230000016173 B cell antigen processing and presentation Effects 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
229940045808 haemophilus influenzae type b Drugs 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Jib Cranes (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Radar Systems Or Details Thereof (AREA)

IL10696893A 1992-09-14 1993-09-10 Potentiation of immunogenic response IL106968A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL13007599A IL130075A0 (en)	1992-09-14	1999-05-23	A vaccine for eliciting an immune response to an antigen in an animal

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US94317392A	1992-09-14	1992-09-14

Publications (2)

Publication Number	Publication Date
IL106968A0 IL106968A0 (en)	1993-12-28
IL106968A true IL106968A (en)	1999-10-28

Family

ID=25479200

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL10696893A IL106968A (en)	1992-09-14	1993-09-10	Potentiation of immunogenic response
IL13007599A IL130075A0 (en)	1992-09-14	1999-05-23	A vaccine for eliciting an immune response to an antigen in an animal

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL13007599A IL130075A0 (en)	1992-09-14	1999-05-23	A vaccine for eliciting an immune response to an antigen in an animal

Country Status (15)

Country	Link
US (4)	US5662909A (no)
EP (1)	EP0588578B2 (no)
JP (1)	JP2512689B2 (no)
AT (1)	ATE187338T1 (no)
AU (1)	AU677592B2 (no)
CA (1)	CA2105629A1 (no)
DE (1)	DE69327214T3 (no)
DK (1)	DK0588578T4 (no)
ES (1)	ES2141750T5 (no)
FI (1)	FI110234B (no)
GR (1)	GR3032543T3 (no)
IL (2)	IL106968A (no)
NO (1)	NO313178B1 (no)
PT (1)	PT588578E (no)
ZA (1)	ZA936629B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6967088B1 (en) *	1995-03-16	2005-11-22	Allergan, Inc.	Soluble recombinant botulinum toxin proteins
US6251405B1 (en) *	1995-06-07	2001-06-26	Connaught Laboratories, Inc.	Immunological combination compositions and methods
ZA964896B (en) *	1995-06-07	1997-01-08	Connaught Lab	Expression of lipoproteins
AU2487300A (en) *	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4776075B2 (ja)	1998-12-31	2011-09-21	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	改変ｈｉｖｅｎｖポリペプチド
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) *	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20050106137A1 (en) *	2000-05-05	2005-05-19	Stephen Grimes	Chimeric peptide immunogens
DE122011100043I1 (de) *	2000-12-27	2011-12-15	Gilead Sciences Inc	Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
EP2280074A3 (en) *	2001-07-05	2011-06-22	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
EP1411770A4 (en) *	2001-07-05	2006-05-10	Chiron Corp	POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
CA2458995C (en) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) *	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7211258B2 (en) *	2002-04-10	2007-05-01	Protalex, Inc.	Protein A compositions and methods of use
US7425331B2 (en) *	2002-04-10	2008-09-16	Protalex, Inc.	Protein A methods of use
US6814729B2 (en)	2002-06-27	2004-11-09	Technovision Gmbh	Laser vision correction apparatus and control method
AU2011230619C1 (en)	2010-03-25	2016-06-23	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
HUE037408T2 (hu)	2011-06-10	2018-08-28	Univ Oregon Health & Science	CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en)	2011-09-12	2013-03-12	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
US10058604B2 (en)	2013-10-07	2018-08-28	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en)	2015-03-20	2017-03-15	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4496538A (en) *	1982-07-06	1985-01-29	Connaught Laboratories, Inc.	Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) *	1982-07-06	1986-10-28	Connaught Laboratories, Inc.	Polysaccharide exotoxoid conjugate vaccines
GB8610983D0 (en) *	1986-05-06	1986-06-11	Connaught Lab	Enhancement of antigen immunogenicity
US4946676A (en) *	1986-08-27	1990-08-07	De Staat Der Nederlanden	Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
EP0270295A3 (en) *	1986-12-03	1989-08-02	Connaught Laboratories Limited	Conjugate vaccine
DK425789A (da) *	1988-08-31	1990-03-01	Smithkline Beecham Corp	Vaccinale polypeptider
JPH0678245B2 (ja) *	1989-07-04	1994-10-05	東興薬品工業株式会社	鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
CA2084413A1 (en) *	1990-06-15	1991-12-16	Richard A. Flavell	Compositions and methods for the prevention and diagnosis of lyme disease
PT100980B (pt) *	1991-10-18	1999-07-30	Connaught Lab	Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao

1993
- 1993-09-07 CA CA002105629A patent/CA2105629A1/en not_active Abandoned
- 1993-09-08 ZA ZA936629A patent/ZA936629B/xx unknown
- 1993-09-08 AU AU46226/93A patent/AU677592B2/en not_active Ceased
- 1993-09-10 IL IL10696893A patent/IL106968A/en not_active IP Right Cessation
- 1993-09-13 DK DK93307185T patent/DK0588578T4/da active
- 1993-09-13 ES ES93307185T patent/ES2141750T5/es not_active Expired - Lifetime
- 1993-09-13 DE DE69327214T patent/DE69327214T3/de not_active Expired - Fee Related
- 1993-09-13 PT PT93307185T patent/PT588578E/pt unknown
- 1993-09-13 AT AT93307185T patent/ATE187338T1/de not_active IP Right Cessation
- 1993-09-13 EP EP93307185A patent/EP0588578B2/en not_active Expired - Lifetime
- 1993-09-13 NO NO19933261A patent/NO313178B1/no unknown
- 1993-09-14 JP JP5229041A patent/JP2512689B2/ja not_active Expired - Lifetime
- 1993-09-14 FI FI934013A patent/FI110234B/fi not_active IP Right Cessation
1995
- 1995-02-08 US US08/385,587 patent/US5662909A/en not_active Expired - Fee Related
- 1995-06-06 US US08/470,278 patent/US5837264A/en not_active Expired - Lifetime
1997
- 1997-02-18 US US08/801,152 patent/US5853736A/en not_active Expired - Fee Related
1998
- 1998-11-17 US US09/193,682 patent/US6024963A/en not_active Expired - Lifetime
1999
- 1999-05-23 IL IL13007599A patent/IL130075A0/xx unknown
2000
- 2000-02-02 GR GR20000400239T patent/GR3032543T3/el unknown

Also Published As

Publication number	Publication date
FI934013L (fi)	1994-03-15
NO313178B1 (no)	2002-08-26
ES2141750T3 (es)	2000-04-01
GR3032543T3 (en)	2000-05-31
DK0588578T3 (da)	2000-03-27
JPH06192125A (ja)	1994-07-12
ZA936629B (en)	1994-03-30
EP0588578B1 (en)	1999-12-08
FI110234B (fi)	2002-12-31
US5853736A (en)	1998-12-29
DE69327214T2 (de)	2000-09-07
EP0588578B2 (en)	2005-04-13
US5662909A (en)	1997-09-02
JP2512689B2 (ja)	1996-07-03
EP0588578A1 (en)	1994-03-23
NO933261D0 (no)	1993-09-13
FI934013A0 (fi)	1993-09-14
ES2141750T5 (es)	2005-12-01
US6024963A (en)	2000-02-15
DK0588578T4 (da)	2005-07-25
ATE187338T1 (de)	1999-12-15
AU677592B2 (en)	1997-05-01
CA2105629A1 (en)	1994-03-15
PT588578E (pt)	2000-05-31
NO933261L (no)	1994-03-15
AU4622693A (en)	1994-03-24
US5837264A (en)	1998-11-17
DE69327214D1 (de)	2000-01-13
IL106968A0 (en)	1993-12-28
DE69327214T3 (de)	2005-12-01
IL130075A0 (en)	2000-02-29

Legal Events

Date	Code	Title
2000-02-29	FF	Patent granted
2000-08-31	KB	Patent renewed
2003-11-23	KB	Patent renewed
2007-10-31	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5837264A (en)	1998-11-17	Potentiation of immunogenic response
US4950480A (en)	1990-08-21	Enhancement of antigen immunogenicity
US5194254A (en)	1993-03-16	Enhancement of antigen immunogenicity
Bona et al.	1998	Towards development of T-cell vaccines
US5686078A (en)	1997-11-11	Primary and secondary immunization with different physio-chemical forms of antigen
JPH04230634A (ja)	1992-08-19	複合ワクチンのキヤリヤー分子としての、百日咳菌の繊維状赤血球凝集素
Bengtsson et al.	1996	Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant
RU2107493C1 (ru)	1998-03-27	Липосомы, осуществляющие тимус-зависимую помощь "слабым" антигенам, используемым для приготовления вакцины
Allison et al.	1992	Immunological adjuvants and their mode of action
Del Giudice	1992	New carriers and adjuvants in the development of vaccines
EP0596959B1 (en)	2000-03-29	Self-adjuvanting peptide vaccine delivery system and production thereof
Allison et al.	1992	Adjuvants for a new generation of vaccines
Allison	1994	Adjuvants and immune enhancement
Robinson et al.	1992	Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells
EP0270295A2 (en)	1988-06-08	Conjugate vaccine
Lövgren-Bengtsson et al.	2000	The ISCOM™ technology
Leibl et al.	1998	Adjuvant/carrier activity of inactivated tick-borne encephalitis virus
Allison	1997	The role of cytokines in the action of immunological adjuvants
US5173293A (en)	1992-12-22	Anti-T-cell antibodies as adjuvants
EP0517743A1 (en)	1992-12-16	Improved immunogenic compositions
Balasa et al.	1993	Immunotargeting of thyroglobulin on antigen presenting cells abrogates natural tolerance in the absence of adjuvant
CA1327523C (en)	1994-03-08	Antigen immunogenicity
Rao et al.	1998	Soluble Proteins Isolated fromBorrelia burgdorferiby Extraction with Triton X-114 Confer Resistance to Experimental Infection
HK1008304B (en)	2000-07-07	Liposomes that provide thymic dependent help to weak vaccine antigens